Prothena reports Q3 net loss of $59M on $1M revenue, cash at $520M; pipeline readouts expected in 2024-2025

PROTHENA CORP PUBLIC LTD CO

2024-Q3 EPS reported -$1.20 revenue$133,034,000

Net loss of $59.0M ($1.10 per share) vs net income of $21.9M ($0.38 diluted) in Q3 2023; revenue fell to $1.0M from $84.9M.
Cash and restricted cash $520.1M as of Sep 30 2024; full-year net cash use guidance reaffirmed at $148-$160M.
Expects topline results from Phase 2b PADOVA (prasinezumab) in 4Q2024 and Phase 3 AFFIRM-AL (birtamimab) in 1H2025.
Phase 1 ASCENT trials (PRX012) for Alzheimer's disease to report multiple readouts starting mid-2025.
Appointed Chad J. Swanson, Ph.D., as Chief Development Officer in September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.